## **National Board of Examinations**

Question Paper Name :	DrNB Medical Gastroenterology Paper3
Subject Name :	DrNB Medical Gastroenterology Paper3
Creation Date :	2024-05-17 19:22:09
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

## **DrNB Medical Gastroenterology Paper3**

Di No Medicai dasti deliterdiogy raper.		
Group Number :	1	
Group Id:	3271871967	
Group Maximum Duration :	0	
Group Minimum Duration :	180	
Show Attended Group? :	No	
Edit Attended Group? :	No	
Group Marks :	100	
Is this Group for Examiner? :	No	
Examiner permission :	Cant View	
Show Progress Bar? :	No	

## **DrNB Medical Gastroenterology Paper3**

**Section Id:** 3271871970

Section Number: 1

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

**Enable Mark as Answered Mark for Review and** 

**Clear Response:** 

Yes

Maximum Instruction Time: 0

Sub-Section Number: 1

**Sub-Section Id:** 3271871974

**Question Shuffling Allowed:** No

Is Section Default?: null

Question Number: 1 Question Id: 32718719282 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Acute Venous Mesenteric Ischemia - Diagnosis, classification and treatment. [3+3+4]

Question Number: 2 Question Id: 32718719283 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

- a) Immunotherapy in Hepatocellular Carcinoma. [6]
- b) PUFA and Colorectal carcinoma. [4]

Question Number: 3 Question Id: 32718719284 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Primary sclerosing cholangitis: definitions, differentials & management. [2+2+6]

Question Number: 4 Question Id: 32718719285 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) JAK inhibitors use in IBD. [5]

b) Role of biomarkers in the management of IBD UC. [5]

Question Number: 5 Question Id: 32718719286 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) PAMPS in liver diseases. [3]

b) Risk score for HCC in HBV. [4]

c) Post liver transplant biliary strictures types and management. [3]

Question Number: 6 Question Id: 32718719287 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) Tumor suppressor genes in carcinoma colon. [5]

b) Pancreatic stellate cells. [5]

Question Number: 7 Question Id: 32718719288 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

## **Correct Marks: 10**

Discuss recent advances in:

- a) Endoscopic Management of GERD. [5]
- b) EUS assisted liver biopsy pro and cons. [5]

Question Number: 8 Question Id: 32718719289 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) Mesenteric Vascular Anatomy. [5]

b) Pathogenesis of Intestinal Pseudo-obstruction. [5]

Question Number: 9 Question Id: 32718719290 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Describe pathogenesis of carcinoma stomach and management of early gastric cancer. [4+6]

Question Number: 10 Question Id: 32718719291 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) Endoscopic bariatric and metabolic therapies. [5]

b) Post-ERCP pancreatitis: Prevention Strategies. [5]